Diagnostic accuracy of the PanbioTM COVID-19 Antigen rapid test device for

2 SARS-CoV-2 detection in Kenya, 2021: A field evaluation

3 Authors

- 4 Irungu Karuga¹, Peninah Munyua², Caroline Ochieng³, Bonventure Juma², Patrick Amoth⁴,
- 5 Francis Kuria⁴, John Kiiru⁴, Lyndah Makayotto⁴, Ahmed Abade¹, Marc Bulterys², Elizabeth
- 6 Hunsperger², Gideon O. Emukule², Clayton Onyango², Taraz Samandari², Beth A. Tippett Barr²,
- 7 Victor Akelo², Herman Weyenga², Patrick K Munywoki², Godfrey Bigogo³, Nancy A. Otieno³,
- 8 Jackton Azenga Kisivuli⁵, Edwin Ochieng⁶, Rufus Nyaga⁶, Noah Hull⁶, Amy Herman-Roloff²,
- 9 and Rashid Aman⁴

10 Author affiliations

- 11 1. Field Epidemiology and Laboratory Training Program, Ministry of Health, Kenya
- 12 2. U.S. Centers for Disease Control and Prevention, Kenya (CDC)
- 13 3. Kenya Medical Research Institute (KEMRI), Center for Global Health Research
- 14 4. Ministry of Health, Kenya
- 15 5. Kenya Prisons Service, Directorate of Health
- 16 6. Association of Public Health Laboratories (APHL)
- 17 **Corresponding author;** Irungu Karuga **email:** *jkarugah@gmail.com*

18 Abstract

- 19 Background: Accurate and timely diagnosis is essential in limiting the spread of severe acute
- 20 respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Real-time reverse transcription-
- 21 polymerase chain reaction (rRT-PCR), the reference standard, requires specialized laboratories,
- 22 costly reagents, and a long turnaround time. Antigen rapid diagnostic tests (Ag RDTs) provide a

23	feasible alternative to rRT-PCR since they are quick, relatively inexpensive, and do not require a
24	laboratory. The WHO requires that Ag RDTs have a sensitivity 80% and specificity 97%.
25	Methods: This evaluation was conducted at 11 health facilities in Kenya between March and
26	July 2021. We enrolled persons of any age with respiratory symptoms and asymptomatic
27	contacts of confirmed COVID-19 cases. We collected demographic and clinical information and
28	two nasopharyngeal specimens from each participant for Ag RDT testing and rRT-PCR. We
29	calculated the diagnostic performance of the Panbio TM Ag RDT against the US Centers for
30	Disease Control and Prevention's (CDC) rRT-PCR test.
31	Results: We evaluated the Ag RDT in 2,245 individuals where 551 (24.5%, 95% CI: 22.8-
32	26.3%) tested positive by rRT-PCR. Overall sensitivity of the Ag RDT was 46.6% (95% CI:
33	42.4-50.9%), specificity 98.5% (95% CI: 97.8-99.0%), PPV 90.8% (95% CI: 86.8-93.9%) and
34	NPV 85.0% (95% CI: 83.4-86.6%). Among symptomatic individuals, sensitivity was 60.6%
35	(95% CI: 54.3-66.7%) and specificity was 98.1% (95% CI: 96.7-99.0%). Among asymptomatic
36	individuals, sensitivity was 34.7% (95% CI 29.3-40.4%) and specificity was 98.7% (95% CI:
37	97.8-99.3%). In persons with onset of symptoms <5 days (594/876, 67.8%), sensitivity was
38	67.1% (95% CI: 59.2-74.3%), and 53.3% (95% CI: 40.0-66.3%) among those with onset of
39	symptoms >7 days (157/876, 17.9%). The highest sensitivity was 87.0% (95% CI: 80.9-91.8%)
40	in symptomatic individuals with cycle threshold (Ct) values 30.
41	Conclusion : The overall sensitivity and NPV of the Panbio [™] Ag RDT were much lower than
42	expected. The specificity of the Ag RDT was high and satisfactory; therefore, a positive result
43	may not require confirmation by rRT-PCR. The kit may be useful as a rapid screening tool for
44	only symptomatic patients in high-risk settings with limited access to RT-PCR. A negative result

- 45 should be interpreted based on clinical and epidemiological information and may require
- 46 retesting by rRT-PCR.
- 47 Keywords: SARS-CoV-2, COVID-19 testing, rapid antigen test, diagnostic tests, PanbioTM,
- 48 symptomatic, asymptomatic, evaluation
- 49

50 Introduction

51	The COVID-19 pandemic has had major negative socioeconomic effects. Prompt diagnosis of
52	SARS-CoV-2 infection is critical in controlling the pandemic. Real-time reverse transcription-
53	polymerase chain reaction (rRT-PCR) remains the reference standard for the diagnosis of SARS-
54	CoV-2 infection. However, rRT-PCR has limitations, including the need for specialized
55	laboratory, equipment, and staff, longer turnaround time (TAT) for clinical decision making and
56	prevention measures, high cost, and erratic supply of reagents to conduct SARS-CoV-2 rRT-
57	PCR due to increased demand (1,2). These limitations have increased the demand for more rapid,
58	cheaper, and easy to perform testing methods.
59	Antigen rapid diagnostic tests (Ag RDTs) increase patients' access to diagnosis of SARS-CoV-2
60	infection. The World Health Organization (WHO) recommends Ag RDTs with a minimum
61	sensitivity and specificity 80% and 97%, respectively where rRT-PCR is unavailable or is
62	associated with long TAT (3).
63	We evaluated the performance of the Panbio [™] Ag RDT compared to the reference standard
64	rRT-PCR. The Panbio [™] Ag RDT is authorized in Kenya and received an emergency use license
65	(EUL) from WHO (4). We also assessed the operational characteristics of the Panbio [™] Ag RDT
66	in the field setting.
67	Methods

We conducted a prospective cross-sectional evaluation of the Panbio[™] Ag RDT in 11 sites in
Kenya between March and July 2021. The sites were located in Nairobi County (Nairobi remand
Prison, Langata Women's Prison, and Tabitha level 2 Clinic), Kiambu County (Kihara Subcounty Hospital), Nakuru County (Nakuru Prison), Nyeri County (Nyeri level 5 Hospital and

72 Nyeri Prison), Kisumu County (Kisumu Prison-Kodiaga), Mombasa County (Coast General 73 Teaching and Referral Hospital) and Siaya County (Siaya County Referral Hospital and St. 74 Elizabeth Mission Hospital). The protocol was reviewed and approved by the Kenya Medical 75 Research Institute's (KEMRI) scientific ethical review unit (SERU). The US Centers for Disease 76 Control and Prevention (CDC) institutional review board provided non-research determination 77 approval. Further administrative approvals were obtained from the Ministry of Health Kenya, the 78 National Commission for Science, Technology, and Innovation (NACOSTI) Kenya, the Kenya 79 Prisons Service, and the county governments of Nakuru, Nyeri, Mombasa, Kiambu, and Siaya. 80 Written informed consent was obtained for all enrolled participants. Written parental informed 81 consent and assent were obtained for participants aged <18 years.

82 Clinical case definition for enrollment

We enrolled persons of any age who presented to our study sites with respiratory symptoms 83 84 (symptomatic participants) that met any of three case definitions, including acute respiratory 85 infection (ARI,) defined as cough or difficulty in breathing or sore throat or coryza, with the 86 onset of symptoms <2 weeks; severe acute respiratory infection (SARI) defined as fever or 87 temperature 38 °C and cough, with onset of symptoms <10 days and requiring hospitalization; 88 or influenza-like illness (ILI) defined as temperature 38°C and cough, with onset of symptoms 89 <10 days. Body temperature measurement was done using infrared thermometers placed 3 to 5 90 centimeters from the temple. We also enrolled asymptomatic close contacts of individuals with 91 confirmed SARS-CoV-2 infection exposed between two days before and 14 days after symptoms 92 onset or confirmation of infection. Individuals exposed to persons with confirmed SARS-CoV-2 93 infection in the following setups were considered close contacts in the following scenarios: 94 working in close proximity or sharing the same environment; face-to-face contact within 1 meter

- 95 for more than 15 minutes; traveling together in any kind of conveyance; living in the same
- 96 household; healthcare-associated exposure, including providing direct care for COVID-19
- 97 patients, visiting patients or staying in the same close environment.

98 Data and specimen collection

99 Individuals who met the case definition and consented were enrolled and assigned unique

100 identifiers. We collected demographic information, and clinical information via electronic

101 questionnaires on smartphones. Data was stored in a secured cloud server. Clinical information

102 collected included the range and duration of respiratory symptoms, presence of comorbidities,

and reported history of exposure to confirmed COVID-19. Two nasopharyngeal swabs were

104 collected by a surveillance officer [nurse, clinical officer, or laboratory technologist] trained to

105 collect respiratory specimens from each of the nostrils a few seconds apart. The first specimen

106 was collected using the swab provided in the Panbio[™] Ag RDT kit. The second specimen was

107 collected using a polyester-tipped aluminum shafted swab and immediately placed in viral

108 transport media at +2 to $+8^{\circ}$ C and shipped to the CDC-supported KEMRI laboratories in

109 Nairobi or Kisumu for rRT-PCR testing where long-term storage was done at -80°C.

110 Rapid SARS-CoV-2 antigen testing

111 Rapid testing was conducted using the PanbioTM Ag RDT (Abbott Rapid Diagnostics, US. Ref.

112 41FK10) per manufacturer instructions by surveillance officers. The Panbio[™] Ag RDT is a

113 lateral flow immunoassay that detects the nucleocapsid (N) protein in nasal and nasopharyngeal

114 specimens(5). Results were read and documented independently by two surveillance officers

115 within 15 to 20 minutes. Positive, negative, and invalid results were interpreted according to the

116 manufacturer's recommendations. Each reader documented the test results in the electronic

- 117 questionnaire independently. In the event the two readers documented different results, the final
- 118 result was indicated as indeterminate.

119 Assessing the operational characteristics of the Panbio[™] Ag RDT kit

- 120 We assessed operational characteristics of the PanbioTM Ag RDT in the field setting including
- 121 clarity of kit instructions, technical complexity or ease of use, and the ease of interpretation of
- 122 results via a standardized questionnaire administered to users on site.

123 RT-PCR testing in the Laboratory

124 According to the manufacturer's instructions, total nucleic acid material was extracted from

- 125 200µL of the nasopharyngeal specimen using either the Ambion MagMax Total RNA isolation
- 126 kit (Thermo Fisher Scientific, Greenville, North Carolina, USA) performed on a semi-automated
- 127 KingFisher flex machine (Thermo Fisher Scientific) or Standard M Spin-X Viral RNA
- 128 Extraction Kit (SD biosensor) according to the manufacturer's instructions. We then eluted 60uL
- 129 of total RNA from the extracted sample. The SARS-CoV-2 rRT-PCR was performed using the
- 130 TaqPath 1-step Multiplex rRT-PCR master mix (Thermo Fisher Scientific) or using the GoTaq®
- 131 Probe 1-Step RT-qPCR System (Promega A6120). Both systems are compatible with the rRT-
- 132 PCR CDC IDT kit. Each of the 15µL reaction volumes contained 5µL of master mix, 8.5µL of
- 133 nuclease-free water, and 1.5µL of CDC-IDT primer/probe mix for each of the N1, N2, and RNP3
- 134 genes separately. The eluate was then amplified using QuantStudio[™] 5 Real-Time PCR System,
- 135 0.1ml block (Thermo Fisher Scientific), and analyses were done using QuantStudio 3 and 5 Real-
- 136 Time PCR System Software version 1.5.1 (Thermo Fisher Scientific). SARS-CoV-2 assay
- 137 targets, N1 and N2 (N1 and N2) were run simultaneously with the human ribonuclease P gene
- 138 (RNP) control to monitor the quality of the nucleic acid extraction, specimen quality, and

presence of reaction inhibitors for assay performance. The positive, negative, and humanspecimen controls were included in all assays.

141 RT-PCR testing

142 When all controls exhibited expected performance, a positive result for SARS-CoV-2 was

143 considered, if all assay amplification curves crossed the threshold line within Ct <40. If SARS-

144 CoV-2 (N1 and N2) assay results were negative, then the test result was reported as negative. If

145 only one target (N1 and N2) were positive, then it was designated as inconclusive, and retesting

146 was conducted. If upon repeating the test, the results remain inconclusive, then the final result

- 147 was reported as inconclusive. Results were relayed back to the specific sites for patient
- 148 management.

149 Sample size calculation

150 To evaluate the diagnostic performance of the Panbio[™] Ag RDT device, we assumed a

151 prevalence of 10% among symptomatic individuals and 5% in asymptomatic contacts of

152 laboratory-confirmed persons based on current SARS CoV 2 local surveillance data. We

assumed a sensitivity of 90% for the Panbio[™] Ag RDT with 7.5% margin of error, and after

adjusting by 10% for other concerns we anticipated enrolling 770 symptomatic patients and

155 1,540 close contacts of confirmed cases.

156 Statistical analysis

157 Statistical analysis was conducted using Stata version 15.1 (College Station, Texas). Measures of 158 central tendency and dispersion were calculated for continuous variables such as age, days since 159 onset of symptoms, temperature, and cycle threshold (Ct) values. We calculated frequencies and 160 proportions for categorical variables such as age group, occupation, and Ct value cut-offs. The

161	95% confidence	intervals for	categorical	variables we	ere calculated	using the normal

- 162 approximation method (Wald's test). We compared proportions between the symptomatic and
- asymptomatic groups by calculating their Z scores. P-values <0.05 were considered statistically
- 164 significant.
- 165 We calculated the sensitivity, specificity, and positive and negative predictive values for the
- 166 PanbioTM Ag RDT against rRT-PCR as the reference standard. Stratified analysis of performance
- 167 was done by age, day's post-onset of symptoms, and Ct values. The measure of agreement
- 168 between Ag RDT and rRT-PCR results was evaluated using Cohen's Kappa statistic. We
- 169 interpreted the strength of agreement as slight agreement (, 0 0.2), fair (, 0.21 0.4), moderate
- 170 (, 0.41 0.6), substantial (, 0.61 0.8), and almost perfect (, 0.81 1.0) as described by Landis et
- 171 *al.* (6).

173 Results

- 174 Enrolled participant characteristics
- 175 We enrolled 2,279 participants, where 38.9% had at least one respiratory symptom. The median
- age was 31.0 years, and over half (60.9%) were male (Table 1). The median duration post-onset
- 177 of symptoms among symptomatic participants was three days, with the majority (67.8%)
- 178 presenting within 5 days.
- 179 Table 1: Clinical and demographic characteristics of participants in the field evaluation of the
- 180 PanbioTM Ag RDT in Kenya, 2021
- 181 Laboratory findings
- 182 Panbio[™] Ag RDT test results
- 183 Among the 2,277 tested using the PanbioTM Ag RDT device, 12.4% were positive (Fig 1). There
- 184 were no invalid or indeterminate Ag RDT results. The positivity was significantly higher among
- symptomatic individuals (18.7%) compared with the asymptomatic (8.4%,) individuals.
- 186 *Fig 1: Flow diagram of enrolment of study participants and distribution by clinical status and*
- 187 test results in the field evaluation of the PanbioTM Ag RDT in Kenya, 2021

188 rRT PCR test results

- 189 We tested 2,277 specimens by rRT-PCR, 24.2% tested positive and 1.4% were inconclusive.
- 190 Positivity (28.7%,) was higher among symptomatic participants compared to asymptomatic
- 191 (21.4%) ones. Among the 32 inconclusive rRT-PCR results, 22 (68.8%) were from
- asymptomatic individuals, and 31 (96.9%) tested negative by Ag RDT (Fig 1). The overall
- 193 median Ct value of the 551 rRT-PCR positive results was 30.2 (IQR 22.9-35.6). Symptomatic

- 194 individuals had a significantly lower median Ct value of 26.2 compared to 33.0 among
- asymptomatic individuals (p < 0.001). The median Ct value was significantly lower among those
- with Ag RDT positive results (23.2) compared to negative test results (35.1) (p < 0.001) (Error!
- 197 **Reference source not found.**).

198 *Error! Reference source not found.*

199 Performance of Panbio[™] Ag RDT

- 200 We reviewed 2,245 paired Ag RDT/rRT-PCR records for the performance analysis. The overall
- 201 sensitivity of the Panbio[™] Ag RDT was 46.6% and specificity was 98.5% (Table 2). At the
- 202 observed SARS-CoV-2 prevalence (24.5%) the positive predictive value (PPV) was 90.8% and
- 203 the negative predictive value (NPV) was 85.0% (Table 2; S1 Fig and S2 Fig). The overall
- agreement between the Ag RDT and rRT-PCR results was moderate (k=0.5,), substantial (k=0.7)
- among the symptomatic, and fair (k=0.4) among the asymptomatic. The performance of the
- 206 Panbio[™] Ag RDT is summarized in Table 2.
- 207 Table 2: The performance of the Panbio[™] Ag RDT by clinical status, and Ct value
- Among the symptomatic participants who were positive for SARS-CoV-2 by rRT-PCR, 100
- 209 (39.4%) had a false negative result by Ag RDT. Two percent (12/632) who were negative for
- 210 SARS-CoV-2 by RT-PCR had a false positive result by Ag RDT. Among the asymptomatic
- 211 individuals, 65.3% (n=194) had a false negative Ag RDT result, and 1.3% (n=14) had a false
- 212 positive result by Ag RDT.

Among the 876 symptomatic participants, the sensitivity was 60.6% (95% CI: 54.3-66.7%) (S3

Fig). Sensitivity in those with days post onset of symptoms <5 was 67.1% and declined to 53.3%

among those with onset >7 days. Among the asymptomatic, sensitivity was significantly lower at

- 216 34.7% (95% CI: 29.3-40.4%) compared to symptomatic individuals (p < 0.001). Specificity
- remained high in symptomatic (98.1%, 95% CI: 96.7-99.0%) and asymptomatic individuals
- 218 (98.7%, 95% CI: 96.7-99.0%) (S4 Fig).
- 219 Regardless of the presence or absence of symptoms, the overall sensitivity of the Ag RDT test in
- 220 273 specimens with Ct values 30 was 81.3% (95% CI: 72.2-91.6). This reduced to 12.6% (95%
- 221 CI: 11.2-14.2%) among the 278 individuals with Ct >30 (Table 2).
- 222 Evaluation of the user's experience of the PanbioTM Ag RDT
- A total of 17 surveillance officers comprising 10 (59%) clinicians and 7 (41%) laboratory staff
- 224 completed the survey. All 17(100%) surveillance officers found the test procedure easy to
- 225 perform, and the manufacturers' instructions were found to be clear and easy to follow. Four
- 226 (23.5%) of the surveillance officers noted the difficulty in dispensing a sample onto the test
- 227 device from the extraction tube when nasopharyngeal specimens were collected from individuals

with thick mucus.

229 Discussion

- 230 We present findings of a field evaluation of the PanbioTM Ag RDT conducted among both
- symptomatic patients with onset of symptoms up to 14 days and asymptomatic individuals who
- had contact with individuals with confirmed SARS-CoV-2 infection within two days before
- detection of the index case and up to 14 days after exposure. Our evaluation was conducted in
- the third COVID-19 wave in Kenya(7,8).
- The overall sensitivity was low (46.6%), detecting slightly less than half of the rRT-PCR
- 236 confirmed cases, therefore, missing more than half and classifying them as not having SARS-
- 237 CoV-2 infection when they were indeed infected. The overall sensitivity we report was lower

238 than observed in studies that enrolled both symptomatic and asymptomatic individuals in a 239 multicenter study in Spain conducted among individuals of any age (57.3%, 95%CI: 48.3-95.8%) 240 (9), Spanish adults in primary care centers (71.4%, 95% CI: 63.1-78.7%) (10), among Spanish 241 individuals of any age (73.3 %, 95 % CI: 62.2–83.8%) (11), and persons of any age presenting 242 within 7 days of onset or exposure (90.5%, 95% CI 87.5-93.6%) (12). 243 The low overall sensitivity observed may be due to the high proportion (61.1%) of asymptomatic 244 participants, and the higher Ct values we observed in these individuals. The lower performance 245 could also be due to the relatively younger (median age 31 years) population we enrolled 246 compared to other studies we reviewed where the median age was higher (39-51.5 years) 247 (11,13). A recent study demonstrated increasing viral load with increasing age (14); higher 248 sensitivities have been observed among individuals with higher viral loads compared to lower 249 ones. The alpha variant and delta variants predominated our evaluation in Kenya (15,16). While 250 some literature indicates that variants of concern (17,18) do not reduce the sensitivity and 251 specificity of Ag RDTs, a recent study revealed that sensitivity of the Panbio[™] Ag RDT 252 declined significantly in individuals infected with the alpha variant (53.0%) compared to those 253 with non-alpha variants (89.0%) even after adjusting for viral load (p < 0.002) (19). Mutations 254 occurring in the N protein of the Alpha variant may not be detected by the PanbioTM Ag RDT 255 (20).

The sensitivity among symptomatic individuals (60.6%) was lower than the WHO recommendation of 80% (21). The sensitivity among symptomatic individuals with onset of symptoms within 7 days was also lower than that reported by the manufacturer on specimens tested on nasopharyngeal specimens (61.6% vs. 91.1%) (5). This is possibly due to the use of specimens with high viral loads by the manufacturer's study for approval as hypothesized by

261 *Albert et al.*, 2021 in an evaluation where SARS-CoV-2 cultures were done (1). Similar

sensitivity was observed in symptomatic Mexican adults (58.1%, 95% CI: 54.9-61.3%) (22).

263 However, the sensitivity we observed among symptomatic individuals was higher compared to

- that reported in a multicenter evaluation conducted among symptomatic children (60.6% vs.
- 45.4%) with the onset of symptoms within five days (13).
- 266 In our evaluation, sensitivity was higher among symptomatic individuals compared to

asymptomatic ones (60.6% vs. 34.7%). Similar findings were observed in other evaluations with

268 higher sensitivity among symptomatic individuals compared to asymptomatic in a study in

269 Mexico (58.1% vs. 26.3%) (22), in Spain (80.4% vs. 56.6%) (10), among Greek children (95.2%

vs. 22.2%) (23), and among Swiss children (73% vs. 43%) (24). However, a German study found

similar sensitivities between the two groups (86.8% vs. 85.7%) (25).

272 Individuals with Ct value 30 had higher sensitivity compared to those with Ct value >30, as 273 observed in other evaluations of PanbioTM Ag RDT (11). The same has been observed in other 274 evaluations considering Ct values 30 (25-27). We also observed higher viral loads among 275 symptomatic individuals (median Ct = 26.2) compared to asymptomatic individuals (median Ct276 = 33.0) from our evaluation (p < 0.001). Similar findings have also been reported recently 277 (28,29). In contrast, some studies found no difference in viral load between the two groups 278 (30,31,) while others found higher viral load among asymptomatic individuals (32,33). Higher 279 sensitivity has been observed among individuals presenting in the early symptomatic phase of 280 their infection (12,22,25–27,34–36). While rRT-PCR testing for SARS-CoV-2 is the reference 281 standard for diagnosis limited access to molecular tests in our setting and provision of results in a 282 clinically relevant timely manner to inform case management limits their clinical utility. 283 Therefore, given reasonable sensitivity, individuals with a negative test in an individual meeting

the clinical and epidemiological criteria may require a confirmatory test by RT-PCR. The
variation in sensitivity by presence or absence of symptoms, symptom duration, and viral load
indicates that the kit may only be useful among individuals with high viral loads, especially those
with symptoms.

The PPV (90.8%) observed at the prevalence of SARS-CoV-2 infection of 24.5% by rRT-PCR

289 was similar to the projected PPV (89.6%.) assuming the minimum recommended sensitivity

290 (80%) and specificity (97.0%). The NPV (85.0%) was lower compared to that computed (93.7%)

assuming the minimum recommendations. Among individuals who tested negative by Ag RDT,

the likelihood of being wrongly classified as uninfected was 15%. In 2021, the median positivity

rate in Kenya was 7.4% (IQR, 3.2-13.1%) (37). At the observed sensitivity and specificity and

the national positivity rate, PPV would range between 50.2% and 82.8%, and the NPV 92.4% -

295 98.2%).

296 The overall specificity we observed (98.5%) was high and was above the WHO recommendation

297 for both symptomatic and asymptomatic individuals and across the other subgroups (21) and was

similar to observations in similar evaluations (22,25,26,35,38–41). The Ag RDT had high

specificity with less than (1.5%) of the tests (n=26) giving a false-positive result. This small

300 proportion represents individuals who would be falsely classified as infected and unnecessarily

301 be managed as COVID-19 cases or self-isolated and their contacts traced and quarantined.

302 However, we observed over half (53%) of the Ag RDT results gave false-negative results with a

303 higher proportion (65%) among the asymptomatic individuals. This observation emphasizes the

304 recommendation by WHO to re-test symptomatic patients with rRT-PCR when they receive a

305 negative Ag RDT result, especially in settings where SARS-CoV-2 prevalence is 5%. Further,

306 as a screening tool for testing contacts of confirmed cases, the 65% false negatives among

307 asymptomatic contacts represent the proportion that would falsely be classified as virus-free, not
 308 self-isolate, and potentially infect others.

- 309 The PanbioTM Ag RDT was found to be easy to use by the majority of the users with a quick
- 310 TAT for clinical decision making and implementation of preventive measures to contain
- 311 transmission as observed in the literature (25,26). The main challenge we observed in conducting
- 312 Ag RDT testing using the PanbioTM Ag RDT kits was dispensing the specimen onto the test
- device in samples collected from individuals with thick mucus. This was, however, solved by
- 314 ensuring that individuals blew their noses before specimen collection.
- 315 Our field evaluation had several strengths. The evaluation was conducted in the real-world
- setting across multiple sites under the point-of-care conditions which had a large sample size
- 317 comprising two groups (symptomatic and asymptomatic individuals) thereby representing
- 318 individuals at any point of the COVID-19 disease spectrum.
- 319 Limitation: The number of persons enrolled in the two groups, symptomatic and asymptomatic,
- may not reflect the true prevalence in the general population as we evaluated the Ag RDT duringa period of high COVID-19 prevalence.

322 Conclusion

- 323 The overall sensitivity and PPV of the Panbio[™] Ag RDT were much lower than expected.
- 324 Sensitivity was acceptable in symptomatic individuals with Ct value 30. Specificity of the Ag
- 325 RDT was high and satisfactory; therefore, a positive result may not require confirmation by rRT-
- 326 PCR. The kit may be useful as a rapid screening tool for only symptomatic patients in high-risk

327	settings with limited access to RT-PCR. A negative result should be interpreted based on clinical
328	and epidemiological information and may require retesting by rRT-PCR.

329 Acknowledgment

- 330 We acknowledge all the study participants, surveillance officers, and laboratory staff that
- participated in this evaluation. In addition, we thank the Ministry of Health Kenya, the Kenya
- 332 Prisons Service, Washington State University (WSU) Global Health Kenya, and the County
- departments of Health of Kiambu, Mombasa, Nakuru, Nyeri, and Siaya for the continued support
- throughout the implementation of the evaluation.

335 Funding

- 336 This project was supported through Cooperative Agreement Number NU2HGH000032, funded
- 337 by the US Centers for Disease Control and Prevention to the Association for Public Health
- 338 Laboratories (APHL). Its contents are solely the responsibility of the authors and do not
- 339 necessarily represent the official views of the US Centers for Disease Control and Prevention or
- 340 the Department of Health and Human Services.

341 Conflict of interest

- 342 The authors declare no conflict of interest.
- 343 Disclaimer: The findings and conclusions in this report are those of the author(s) and do not
- 344 necessarily represent the official position of the U.S. Centers for Disease Control and Prevention.
- 345 Use of trade names is for identification only and does not imply endorsement by [the Centers for
- 346 Disease Control and Prevention/the Agency for Toxic Substances and Disease Registry], the
- 347 Public Health Service, or the U.S. Department of Health and Human Services

348 References

349	1.	Albert E, Torres I, Bueno F, Huntley D, Molla E, Fernández-Fuentes MÁ, et al. Field
350		evaluation of a rapid antigen test (Panbio TM COVID-19 Ag Rapid Test Device) for
351		COVID-19 diagnosis in primary healthcare centres. Clin Microbiol Infect [Internet]. 2021
352		Mar;27(3):472.e7-472.e10. Available from:
353		https://linkinghub.elsevier.com/retrieve/pii/S1198743X20306972
354	2.	Barra GB, Rita THS, Mesquita PG, Jácomo RH, Nery LFA. Overcoming supply shortage
355		for SARS-CoV-2 detection by RT-qPCR. Genes (Basel). 2021;12(1):1–10.
356	3.	World Health Organization (WHO). Antigen-detection in the diagnosis of SARS-CoV-2
357		infection using rapid immunoassays Interim guidance, 11 September 2020. World Heal
358		Organ [Internet]. 2020;(September):1–9. Available from:
359		https://www.who.int/publications/i/item/antigen-detection-in-the-diagnosis-of-sars-cov-inter-detection-in-the-diagnosis-of-sars-cov-inter-detection-in-the-diagnosis-of-sars-cov-inter-detection-in-the-diagnosis-of-sars-cov-inter-detection-in-the-diagnosis-of-sars-cov-inter-detection-in-the-diagnosis-of-sars-cov-inter-detection-in-the-diagnosis-of-sars-cov-inter-detection-in-the-diagnosis-of-sars-cov-inter-detection-in-the-diagnosis-of-sars-cov-inter-detection-in-the-diagnosis-of-sars-cov-inter-detection-in-the-diagnosis-of-sars-cov-inter-detection-in-the-diagnosis-of-sars-cov-inter-detection-in-the-diagnosis-of-sars-cov-inter-detection-inter-detection-in-the-diagnosis-of-sars-cov-inter-detection-inter-detection-inter-detection-inter-detection-inter-detection-inter-detection-inter-detection-inter-detection-inter-detection-inter-detection-inter-detection-inter-detection-inter-detection-inter-detection-inter-detection-inter-detection-inter-detection-inter-detection-inter-detection-inter-detection-inter-detection-inter-detection-inter-detection-inter-detection-inter-detection-inter-detection-inter-detection-inter-detection-inter-detection-inter-detection-inter-detection-inter-detection-inter-detection-inter-detection-inter-detection-inter-detection-inter-detection-inter-detection-inter-detection-inter-detection-inter-detection-inter-detection-inter-detection-inter-detection-inter-detection-inter-detection-inter-detection-inter-detection-inter-detection-inter-detection-inter-detection-inter-detection-inter-detection-inter-detection-inter-detection-inter-detection-inter-detection-inter-detection-inter-detection-inter-detection-inter-detection-inter-detection-inter-detection-inter-detection-inter-detection-inter-detection-inter-detection-inter-detection-inter-detection-inter-detection-inter-detection-inter-detection-inter-detection-inter-detection-inter-detection-inter-detection-inter-detection-inter-detection-inter-detection-inter-detection-inter-detection-inter-detection-inter-detection-inter-detection-inter-detect
360		2infection-using-rapid-immunoassays%0Ahttps://apps.who.int/iris/handle/10665/334253
361	4.	World Health Organization (WHO). WHO Emergency Use Listing for In vitro diagnostics
362		(IVDs) Detecting SARS-CoV-2. Geneva [Internet]. World Health Organization (WHO).
363		Geneva; 2020. Available from:
364		https://extranet.who.int/pqweb/sites/default/files/documents/210217_eul_sars-
365		$cov2_product_list.pdf\%0Ahttps://www.who.int/diagnostics_laboratory/201002_eul_sars_laboratory/201002_eul_sars_laboratory/201002_eul_sars_laboratory/201002_eul_sars_laboratory/201002_eul_sars_laboratory/201002_eul_sars_laboratory/201002_eul_sars_laboratory/201002_eul_sars_laboratory/201002_eul_sars_laboratory/201002_eul_sars_laboratory/201002_eul_sars_laboratory/201002_eul_sars_laboratory/201002_eul_sars_laboratory/201002_eul_sars_laboratory/201002_eul_sars_laboratory/201002_eul_sars_laboratory/201002_eul_sars_laboratory/201002_eul_sars_laboratory/201002_eul_sars_laboratory/201002_eul_sars_laboratory/201002_eul_sars_laboratory/201002_eul_sars_laboratory/201002_eul_sars_laboratory/201002_eul_sars_laboratory/201002_eul_sars_laboratory/201002_eul_sars_laboratory/201002_eul_sars_laboratory/201002_eul_sars_laboratory/201003_eul_sars_laboratory/201003_eul_sars_laboratory/201003_eul_sars_laboratory/201003_eul_sars_laboratory/201003_eul_sars_laboratory/201003_eul_sars_laboratory/201003_eul_sars_laboratory/201004_eul_sars_laboratory/20103_eul_sars_laboratory/20103_eul_sars_laboratory/201004_eul_sars_laboratory/201004_eul_sars_laboratory/201004_eul_sars_laboratory/201004_eul_sars_laboratory/201004_eul_sars_laboratory/201004_eul_sars_laboratory/201004_eul_sars_laboratory/201004_eul_sars_laboratory/20104_eul_sars_laboratory/20104_eul_sars_laboratoratory/20104_eul_sars_laboratory/20104_eul_sars_laboratoratoratoratoratoratoratoratoratorat$
366		cov2_product_list.pdf?ua=1
367	5.	Abbott. Panbio TM Test Device COVID-19 Ag Rapid -In vitro diagnostic rapid test for
368		qualitative detection of SARS-CoV-2 antigen (Ag) [Internet]. 2021. Available from:
369		https://dam.abbott.com/en-gb/panbio/120007883-v1-Panbio-COVID-19-Ag-Nasal-
370		AsymptomaticSe.pdf
371	6.	Landis JR, Koch GG. The Measurement of Observer Agreement for Categorical Data.
372		Biometrics [Internet]. 1977 Mar;33(1):159. Available from:
373		https://www.jstor.org/stable/2529310?origin=crossref
374	7.	Ministry of Health Kenya. Covid-19 Outbreak in Kenya Situation report 670. Vol. 670.
375		2021.

376377378379	8.	World Health Organization W. WHO Coronavirus Disease (COVID-19) Dashboard With Vaccination Data WHO Coronavirus (COVID-19) Dashboard With Vaccination Data [Internet]. World Health Organization. 2022 [cited 2022 Feb 20]. Available from: https://covid19.who.int/region/afro/country/ke
380381382	9.	Agulló V, Fernández-González M, Ortiz de la Tabla V, Gonzalo-Jiménez N, García JA, Masiá M, et al. Evaluation of the rapid antigen test Panbio COVID-19 in saliva and nasal swabs in a population-based point-of-care study. J Infect. 2021;82(5):186–230.
383 384 385 386	10.	Bulilete O, Lorente P, Leiva A, Carandell E, Oliver A, Rojo E, et al. Panbio TM rapid antigen test for SARS-CoV-2 has acceptable accuracy in symptomatic patients in primary health care. J Infect [Internet]. 2021 Mar;82(3):391–8. Available from: https://doi.org/10.1016/j.jinf.2021.02.014
387 388 389 390	11.	Linares M, Pérez-Tanoira R, Carrero A, Romanyk J, Pérez-García F, Gómez-Herruz P, et al. Panbio antigen rapid test is reliable to diagnose SARS-CoV-2 infection in the first 7 days after the onset of symptoms. J Clin Virol [Internet]. 2020 Dec;133(January):104659. Available from: https://linkinghub.elsevier.com/retrieve/pii/S1386653220304017
391 392 393	12.	Merino P, Guinea J, Muñoz-Gallego I, González-Donapetry P, Galán JC, Antona N, et al. Multicenter evaluation of the Panbio TM COVID-19 rapid antigen-detection test for the diagnosis of SARS-CoV-2 infection. Clin Microbiol Infect. 2021;27(5):758–61.
 394 395 396 397 398 399 	13.	Villaverde S, Domínguez-Rodríguez S, Sabrido G, Pérez-Jorge C, Plata M, Romero MP, et al. Diagnostic Accuracy of the Panbio Severe Acute Respiratory Syndrome Coronavirus 2 Antigen Rapid Test Compared with Reverse-Transcriptase Polymerase Chain Reaction Testing of Nasopharyngeal Samples in the Pediatric Population. J Pediatr [Internet]. 2021 May;232(January):287-289.e4. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0022347621000342
400 401 402 403	14.	Euser S, Aronson S, Manders I, van Lelyveld S, Herpers B, Sinnige J, et al. SARS-CoV-2 viral-load distribution reveals that viral loads increase with age: a retrospective cross-sectional cohort study. Int J Epidemiol [Internet]. 2022 Jan 6;50(6):1795–803. Available from: https://academic.oup.com/ije/article/50/6/1795/6366466

- 404 15. KEMRI. Genomic surveillance detects local transmission of the global variants of concern
 405 in nine counties in Kenya. 2021.
- 406 16. Kimita G, Nyataya J, Omuseni E, Sigei F, Lemtudo A, Muthanje E, et al. A genomics
- 407 dissection of Kenya's COVID-19 waves: temporal lineage replacements and dominance of
- 408 imported variants of concern. 2021; Available from:
- 409 https://www.researchsquare.com/article/rs-942627/v1
- 410 17. Bekliz M, Adea K, Essaidi-Laziosi M, Sacks JA, Escadafal C, Kaiser L, et al. SARS-
- 411 CoV-2 rapid diagnostic tests for emerging variants. The Lancet Microbe [Internet].
- 412 2021;2(8):e351. Available from: http://dx.doi.org/10.1016/S2666-5247(21)00147-6
- 413 18. Bekliz M, Adea K, Essaidi-Laziosi M, Sacks JA, Escadafal C, Kaiser L, et al. SARS-
- 414 CoV-2 antigen-detecting rapid tests for the delta variant. The Lancet Microbe [Internet].
- 415 2022 Feb;3(2):e90. Available from: http://dx.doi.org/10.1016/S2666-5247(21)00302-5
- 416 19. van Ogtrop ML, van de Laar TJW, Eggink D, Vanhommerig JW, van der Reijden WA.
- 417 Comparison of the Performance of the PanBio COVID-19 Antigen Test in SARS-CoV-2
- 418 B.1.1.7 (Alpha) Variants versus non-B.1.1.7 Variants. Wesley Long S, editor. Microbiol
- 419 Spectr [Internet]. 2021 Dec 22;9(3):1–22. Available from:
- 420 https://journals.asm.org/doi/10.1128/Spectrum.00884-21
- 421 20. Jian MJ, Chung HY, Chang CK, Lin JC, Yeh KM, Chen CW, et al. SARS-CoV-2 variants
 422 with T135I nucleocapsid mutations may affect antigen test performance. Int J Infect Dis
 423 [Internet]. 2022;114:112–4. Available from: https://doi.org/10.1016/j.ijid.2021.11.006
- 424 21. World Health Organization. SARS-CoV-2 Antigen detecting rapid diagnostic test
 425 implementation projects [Internet]. 2020. p. 1–6. Available from:
- 426 https://www.who.int/news-room/articles-detail/sars-cov-2-antigen-detecting-rapid427 diagnostic-test-implementation-projects
- 428 22. Thirion-Romero I, Guerrero-Zúñiga DS, Arias-Mendoza DA, Cornejo-Juárez DDP, Meza-
- 429 Meneses DP, Torres-Erazo DDS, et al. Evaluation of Panbio rapid antigen test for SARS
- 430 CoV 2 in symptomatic patients and their contacts: a multicenter study. Int J Infect Dis
- 431 [Internet]. 2021 Dec;113:218–24. Available from:

432		https://linkinghub.elsevier.com/retrieve/pii/S1201971221008110
433 434 435	23.	Eleftheriou I, Dasoula F, Dimopoulou D, Lebessi E, Serafi E, Spyridis N, et al. Real-life evaluation of a COVID-19 rapid antigen detection test in hospitalized children. J Med Virol. 2021;93(10):6040–4.
436 437 438	24.	L'Huillier AG, Lacour M, Sadiku D, Gadiri MA, De Siebenthal L, Schibler M, et al. Diagnostic accuracy of sars-cov-2 rapid antigen detection testing in symptomatic and asymptomatic children in the clinical setting. J Clin Microbiol. 2021;59(9):1–8.
 439 440 441 442 443 	25.	Krüger LJ, Gaeddert M, Tobian F, Lainati F, Gottschalk C, Klein JAF, et al. The Abbott PanBio WHO emergency use listed, rapid, antigen-detecting point-of-care diagnostic test for SARS-CoV-2—Evaluation of the accuracy and ease-of-use. Mantis NJ, editor. PLoS One [Internet]. 2021 May 27;16(5):e0247918. Available from: https://dx.plos.org/10.1371/journal.pone.0247918
444 445 446	26.	FIND. FIND Evaluation of Abbott Panbio COVID-19 Ag Rapid Test Device External Report. 2020;(December):1–4. Available from: https://www.finddx.org/wp- content/uploads/2020/12/Panbio_Ag-Public-Report_v2.1.pdf
447 448 449 450	27.	Alemany A, Baró B, Ouchi D, Rodó P, Ubals M, Corbacho-Monné M, et al. Analytical and clinical performance of the panbio COVID-19 antigen-detecting rapid diagnostic test. J Infect [Internet]. 2021 May;82(5):186–230. Available from: https://linkinghub.elsevier.com/retrieve/pii/S0163445321000050
451 452 453 454	28.	Almadhi MA, Abdulrahman A, Sharaf SA, AlSaad D, Stevenson NJ, Atkin SL, et al. The high prevalence of asymptomatic SARS-CoV-2 infection reveals the silent spread of COVID-19. Int J Infect Dis [Internet]. 2021;105:656–61. Available from: https://doi.org/10.1016/j.ijid.2021.02.100
455 456 457 458 459	29.	Strutner J, Ramchandar N, Dubey S, Gamboa M, Vanderpool MK, Mueller T, et al. Comparison of Reverse-Transcription Polymerase Chain Reaction Cycle Threshold Values From Respiratory Specimens in Symptomatic and Asymptomatic Children With Severe Acute Respiratory Syndrome Coronavirus 2 Infection. Clin Infect Dis [Internet]. 2021 Nov 16;73(10):1790–4. Available from:

460		https://academic.oup.com/cid/article/73/10/1790/6266745
461	30.	Zuin M, Gentili V, Cervellati C, Rizzo R, Zuliani G. Viral load difference between
462 463		symptomatic and asymptomatic COVID-19 patients: Systematic review and meta- analysis. Infect Dis Rep. 2021;13(3):645–53.
464 465	31.	Lavezzo E, Franchin E, Ciavarella C, Cuomo-Dannenburg G, Barzon L, Del Vecchio C, et al. Suppression of a SARS-CoV-2 outbreak in the Italian municipality of Vo'. Nature
466		[Internet]. 2020 Aug 20;584(7821):425–9. Available from:
467		http://www.nature.com/articles/s41586-020-2488-1
468	32.	Cardillo L, de Martinis C, Viscardi M, Esposito C, Sannino E, Lucibelli G, et al. SARS-
469		CoV-2 quantitative real time PCR and viral loads analysis among asymptomatic and
470		symptomatic patients: an observational study on an outbreak in two nursing facilities in
471		Campania Region (Southern Italy). Infect Agent Cancer. 2021;16(1):1–7.
472	33.	Hasanoglu I, Korukluoglu G, Asilturk D, Cosgun Y, Kalem AK, Altas AB, et al. Higher
473		viral loads in asymptomatic COVID-19 patients might be the invisible part of the iceberg.
474		Infection [Internet]. 2021;49(1):117-26. Available from: https://doi.org/10.1007/s15010-
475		020-01548-8
476	34.	He X, Lau EHY, Wu P, Deng X, Wang J, Hao X, et al. Temporal dynamics in viral
477		shedding and transmissibility of COVID-19. Nat Med. 2020;26(5):672-5.
478	35.	Berger A, Nsoga MTN, Perez-Rodriguez FJ, Aad YA, Sattonnet-Roche P, Gayet-Ageron
479		A, et al. Diagnostic accuracy of two commercial SARSCoV- 2 antigen-detecting rapid
480		tests at the point of care in community-based testing centers. PLoS One. 2021;16(3 March
481		2021):1–12.
482	36.	Ferté T, Ramel V, Cazanave C, Lafon M-E, Bébéar C, Malvy D, et al. Accuracy of
483		COVID-19 rapid antigenic tests compared to RT-PCR in a student population: The
484		StudyCov study. J Clin Virol [Internet]. 2021 Aug;141(January):104878. Available from:
485		https://linkinghub.elsevier.com/retrieve/pii/S1386653221001451
486	37.	Hasell J, Mathieu E, Beltekian D, Macdonald B, Giattino C, Ortiz-Ospina E, et al. A
487		cross-country database of COVID-19 testing. Sci Data [Internet]. 2020 Dec 8 [cited 2022

488		Feb 20];7(1):345. Available from: https://ourworldindata.org/coronavirus-testing
489	38.	Albert E, Torres I, Bueno F, Huntley D, Molla E, Fernández-Fuentes MÁ, et al. Field
490		evaluation of a rapid antigen test (Panbio TM COVID-19 Ag Rapid Test Device) for
491		COVID-19 diagnosis in primary healthcare centres. Clin Microbiol Infect [Internet].
492		2021;27(3):472.e7-472.e10. Available from: https://doi.org/10.1016/j.cmi.2020.11.004
493	39.	Christensen A, Larsdatter M, Landaas E, Bragstad K, Kran A-MB, Tollånes M, et al.
494		Evaluation of Abbot's Panbio COVID -19 rapid antigen test in Norway [Internet]. 2020.
495		Available from: https://www.helsedirektoratet.no/rapporter/evaluation-of-abbots-panbio-
496		covid-19-rapid-antigen-test-in-norway/Evaluation of Abbots Panbio COVID-19 rapid
497		antigen test in Norway.pdf/_/attachment/inline/b3306b98-c0e0-4e96-aa62-
498		3ca5a99f5367:10fe6f072721ece7aee
499	40.	Torres I, Poujois S, Albert E, Colomina J, Navarro D. Evaluation of a rapid antigen test
500		(Panbio TM COVID-19 Ag rapid test device) for SARS-CoV-2 detection in asymptomatic
501		close contacts of COVID-19 patients. Clin Microbiol Infect [Internet]. 2021
502		Apr;27(4):636.e1-636.e4. Available from:
503		https://linkinghub.elsevier.com/retrieve/pii/S1198743X20307825
504	41.	Dinnes J, Deeks JJ, Berhane S, Taylor M, Adriano A, Davenport C, et al. Rapid, point-of-
505		care antigen and molecular-based tests for diagnosis of SARS-CoV-2 infection. Cochrane
506		Database Syst Rev [Internet]. 2021 Mar 24;2021(4). Available from:
507		http://doi.wiley.com/10.1002/14651858.CD013705.pub2
508		

510 Tables

Variable	Symptomatic (886) n (%)	Asymptomatic (1,393) n (%)	Total (2,279) n (%)	P-value
Sex				
Male	510 (57.6)	877 (63.0)	1387 (60.9)	0.01
Female	376 (42.4)	516 (37.0)	892 (39.1)	0.01
Symptoms				
Cough	604 (68.4)	-	-	-
Fever	294 (33.2)	-	-	-
Runny nose	266 (30.1)	-	-	-
Headache	231 (26.2)	-	-	-
Sore throat	197 (22.2)	-	-	-
Shortness of breath	195 (22.0)	-	-	-
Duration since onset				
<5 days	601 (67.8)	-	-	
5- 7 days	126 (14.2)	-	-	
7-14 days	159 (18.0)	-	-	
7 days	814 (91.9)	-	-	
>7-14 days	72 (8.1)	-	-	
Comorbidities and underlying condition	ons			
Cardiovascular disease, including hypertension	87 (9.8)	13 (0.9)	100 (4.4)	< 0.001
Immunodeficiency, including HIV	31 (3.5)	25 (1.8)	56 (2.5)	0.011
Diabetes	18 (2.0)	6 (0.4)	24 (1.1)	< 0.001
Other conditions	43 (4.7)	34 (2.3)	77 (3.2)	0.002
No known comorbidities	720 (81.1)	1266 (90.4)	1986 (86.8)	< 0.001
Other risk factors				
Smoking (current or former smoker)	11 (1.2)	53 (3.8)	64 (2.8)	< 0.001
Occupational settings				
Inmates and prison warders	265 (29.8)	1034 (73.9)	1299 (56.8)	< 0.001
Health care workers	72 (8.1)	109 (7.8)	181 (7.9)	0.942
Learning institutions	103 (11.6)	64 (4.6)	167 (7.3)	0.123
Preschool	117 (13.2)	21 (1.5)	138 (6)	0.945
Other employment	287 (32.3)	171 (12.2)	458 (20.1)	< 0.001
Missing	44 (5)	1 (0.1)	45 (2)	-

511 Table 1: Clinical and demographic characteristics of participants in the field evaluation of the PanbioTM Ag RDT in Kenya, 2021

512 n, number of; HIV, human immunodeficiency virus

	n	Ag RDT +ve	rRT- PCR +ve	Ag RDT -ve	rRT- PCR -ve	Sensitivity % (95% CI)	Specificity % (95% CI)	PPV % (95% CI)	NPV % (95% CI)	Kappa k (95% CI)
Cases										
All	2,245	257	551	1,668	1,694	46.6 (42.4-50.9)	98.5 (97.8-99.0)	90.8 (86.8-93.9)	85.0 (83.4-86.6)	0.5 (0.5-0.6)
Symptomatic	876	154	254	610	622	60.6 (54.3-66.7)	98.1 (96.7-99.0)	92.8 (87.7-96.2)	85.9 (83.1-88.4)	0.7 (0.6-0.7)
Asymptomatic	1,369	103	297	1,058	1,072	34.7 (29.3-40.4)	98.7 (97.8-99.3)	88.0 (80.7-93.3)	84.5 (82.4-86.5)	0.4 (0.4-0.5)
Days post onset of	symptom									
<5 days	594	106	158	428	436	67.1 (59.2-74.3)	98.2 (96.4-99.2)	93.0 (86.6-96.9)	89.2 (86.0-91.8)	0.7 (0.6-0.8)
5-7 days	125	16	36	87	89	44.4 (27.9-61.9)	97.8 (92.1-99.7)	88.9 (65.3-98.6)	81.3 (72.6-88.2)	0.5 (0.3-0.7)
>7-14 days	157	32	60	95	97	53.3 (40.0-66.3)	97.9 (92.7-99.7)	94.1 (80.3-99.3)	77.2 (68.8-84.3)	0.6 (0.4-0.7)
7 days	805	146	237	557	568	61.6 (55.1-67.8)	98.1 (96.6-99.0)	93.0 (87.8-96.5)	86.0 (83.0-88.5)	0.7 (0.6-0.7)
>7-14 days	71	8	17	53	54	47.1 (23.0-72.2)	98.1 (90.1- 100.0)	88.9 (51.8-99.7)	85.5 (74.2-93.1)	0.5 (0.3-0.8)
Ct value 30							-			
All	273	222	273	-	-	81.3 (72.2-91.6)	-	-	-	-
Symptomatic	162	141	162	-	-	87.0 (80.9-91.8)	-	-	-	-
Asymptomatic	111	81	111	-	-	73.0 (60.6-87.9)	-	-	-	-
<i>Ct value >30 - <40</i>)									
All	278	35	278	-	-	12.6 (11.2-14.2)	-	-	-	-
Symptomatic	92	13	92	-	-	14.1 (7.7-23.0)	-	-	-	-
Asymptomatic	186	22	186	-	-	11.8 (10.2-13.7)	-	-	-	-

513 Table 2: The performance of the PanbioTM Ag RDT by clinical status, and Ct value

n, number of; Ag RDT, antigen rapid diagnostic test; CI, confidence interval; PPV, positive predictive value; NPV, negative

515 predictive value; Ct, cycle threshold

516 Figures



Fig 1: Flow diagram of enrolment of study participants and distribution by clinical status and test results in the field evaluation of the Panbio[™] Ag RDT in Kenya, 2021

517 Ag RDT, Antigen rapid diagnostic test; rRT-PCR, real-time reverse transcriptase-polymerase

518 chain reaction



520 Fig 2: Distribution of Cycle threshold (Ct) values for rRT-PCR positive samples by Ag RDT

- 521 result and by presence/absence of symptoms, Kenya 2021 (n=551)
- 522 Ag RDT, Antigen rapid diagnostic test; Ct, cycle threshold

523 Supporting information



525 S1 Fig: The Positive Predictive Value of the Panbio[™] Ag RDT by clinical status and days post onset of symptoms, Kenya 2021



526

524

527 S2 Fig: The Negative Predictive Value of the Panbio[™] Ag RDT by clinical status and days post onset of symptoms, Kenya 2021



530 S3 Fig: The sensitivity of the PanbioTM Ag RDT by clinical status, and Ct values



532 S4 Fig: The specificity of the Panbio[™] Ag RDT by clinical status and days post onset of symptoms, Kenya 2021